Top

Published in:

01-10-2021 | Magnetic Resonance Imaging | Oncology

Noninvasive prediction of residual disease for advanced high-grade serous ovarian carcinoma by MRI-based radiomic-clinical nomogram

Authors: Haiming Li, Rui Zhang, Ruimin Li, Wei Xia, Xiaojun Chen, Jiayi Zhang, Songqi Cai, Yong’ai Li, Shuhui Zhao, Jinwei Qiang, Weijun Peng, Yajia Gu, Xin Gao

Published in: European Radiology | Issue 10/2021

Abstract

Objectives

To develop a preoperative MRI-based radiomic-clinical nomogram for prediction of residual disease (RD) in patients with advanced high-grade serous ovarian carcinoma (HGSOC).

Methods

In total, 217 patients with advanced HGSOC were enrolled from January 2014 to June 2019 and randomly divided into a training set (n = 160) and a validation set (n = 57). Finally, 841 radiomic features were extracted from each tumor on T2-weighted imaging (T2WI) and contrast-enhanced T1-weighted imaging (CE-T1WI) sequence, respectively. We used two fusion methods, the maximal volume of interest (MV) and the maximal feature value (MF), to fuse the radiomic features of bilateral tumors, so that patients with bilateral tumors have the same kind of radiomic features as patients with unilateral tumors. The radiomic signatures were constructed by using mRMR method and LASSO classifier. Multivariable logistic regression analysis was used to develop a radiomic-clinical nomogram incorporating radiomic signature and conventional clinico-radiological features. The performance of the nomogram was evaluated on the validation set.

Results

In total, 342 tumors from 217 patients were analyzed in this study. The MF-based radiomic signature showed significantly better prediction performance than the MV-based radiomic signature (AUC = 0.744 vs. 0.650, p = 0.047). By incorporating clinico-radiological features and MF-based radiomic signature, radiomic-clinical nomogram showed favorable prediction ability with an AUC of 0.803 in the validation set, which was significantly higher than that of clinico-radiological signature and MF-based radiomic signature (AUC = 0.623, 0.744, respectively).

Conclusions

The proposed MRI-based radiomic-clinical nomogram provides a promising way to noninvasively predict the RD status.

Key Points

• MRI-based radiomic-clinical nomogram is feasible to noninvasively predict residual disease in patients with advanced HGSOC.

• The radiomic signature based on MF showed significantly better prediction performance than that based on MV.

• The radiomic-clinical nomogram showed a favorable prediction ability with an AUC of 0.803.

Available only for authorised users

Wentzensen N, Poole EM, Trabert B et al (2016) Ovarian cancer risk factors by histologic subtype: An analysis from the Ovarian Cancer Cohort Consortium. J Clin Oncol 34:2888–2898PubMedPubMedCentralCrossRef

Cybulska P, Stewart JM, Sayad A et al (2018) A genomically characterized collection of high-grade serous ovarian cancer xenografts for preclinical testing. Am J Pathol 188:1120–1131PubMedCrossRef

Verhaak RG, Tamayo P, Yang JY et al (2013) Prognostically relevant gene signatures of high-grade serous ovarian carcinoma. J Clin Invest 123:517–525PubMed

Chang SJ, Bristow RE, Ryu HS (2012) Impact of complete cytoreduction leaving no gross residual disease associated with radical cytoreductive surgical procedures on survival in advanced ovarian cancer. Ann Surg Oncol 19:4059–4067PubMedCrossRef

du Bois A, Reuss A, Pujade-Lauraine E et al (2009) Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: A combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials: by the Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR) and the Groupe d'Investigateurs Nationaux Poue Ies Etudes des Cancers de I'Ovaire (GINECO). Cancer 115:1234–1244PubMedCrossRef

Fagotti A, Vizzielli G, Fanfani F et al (2015) Introduction of staging laparoscopy in the management of advanced epithelial ovarian, tubal and peritoneal cancer: Impact on prognosis in a single institution experience. Gynecol Oncol 131:341–346CrossRef

Kehoe S, Hook J, Nankivell M et al (2015) Primary chemotherapy versus primary surgery for newly diagnosed advanced ovarian cancer (CHORUS): An open-label, randomised, controlled non-inferiority trial. Lancet 386:249–257PubMedCrossRef

Vergote I, Tropé CG, Amant F et al (2010) Neoadjuvant chemotherapy or primary surgery in stage IIIc or IV ovarian cancer. N Engl J Med 363:943–953PubMedCrossRef

Ghirardi V, Moruzzi MC, Bizzarri N et al (2020) Minimal residual disease at primary debulking surgery versus complete tumor resection at interval debulking surgery in advanced epithelial ovarian cancer: A survival analysis. Gynecol Oncol 157:209–213PubMedCrossRef

10.

Fagotti A, Ferrandina G, Fanfani F et al (2006) A laparoscopy-based score to predict surgical outcome in patients with advanced ovarian carcinoma: A pilot study. Ann Surg Oncol 13:1156–1161PubMedCrossRef

11.

van de Vrie R, Rutten MJ, Asseler JD et al (2019) Laparoscopy for diagnosing resectability of disease in women with advanced cancer. Cochrane Database Syst Rev 3:CD009786PubMed

12.

Suidan RS, Ramirez PT, Sarasohn DM et al (2014) A multicenter prospective trial evaluating the ability of preoperative computed tomography scan and serum CA-125 to predict suboptimal cytoreduction at primary debulking surgery for advanced ovarian, fallopian tube, and peritoneal cancer. Gynecol Oncol 134:455–461PubMedPubMedCentralCrossRef

13.

Bristow RE, Duska LR, Lambrou NC et al (2000) A model for predicting surgical outcome in patients with advanced ovarian carcinoma using computed tomography. Cancer 89:1532–1540PubMedCrossRef

14.

Dowdy SC, Mullany SA, Brandt KR, Huppert BJ, Cliby WA (2004) The utility of computed tomography scans in predicting suboptimal cytoreductive surgery in women with advanced ovarian cancer. Cancer 101:346–352PubMedCrossRef

15.

Axtell AE, Lee MH, Bristow RE et al (2007) Multi-institutional reciprocal validation study of computed tomography predictors of suboptimal primary cytoredcution in patients with advanced ovarian cancer. J Clin Oncol 25:384–389PubMedCrossRef

16.

Feng Z, Wen H, Jiang Z et al (2018) A triage strategy in advanced ovarian cancer management based on multiple predictive models for R0 resection: A prospective cohort study. J Gynecol Oncol 29:e65PubMedPubMedCentralCrossRef

17.

Lambin P, Leijenaar RTH, Deist TM et al (2017) Radiomics: The bridge between medical imaging and personalized medicine. Nat Rev Clin Oncol 14:749–762PubMedCrossRef

18.

Dong D, Tang L, Li ZY et al (2019) Development and validation of an individualized nomogram to identify occult peritoneal metastasis in patients with advanced gastric cancer. Ann Oncol 30:431–438PubMedPubMedCentralCrossRef

19.

Liu ZY, Zhang XY, Shi YJ et al (2017) Radiomics analysis for evaluation of pathological complete response to neoadjuvant chemotherapy in locally advanced rectal cancer. Clin Cancer Res 23:7253–7262PubMedCrossRef

20.

Peng H, Dong D, Fang MJ et al (2019) Prognostic value of deep learning PET/CT-based radiomics: Potential role for future individual induction chemotherapy in advanced nasopharyngeal carcinoma. Clin Cancer Res 25:4271–4279PubMedCrossRef

21.

Nougaret S, Nikolovski I, Paroder V et al (2019) MRI of tumors and tumor mimics in the female pelvis: Anatomic pelvic space-based approach. Radiographics 39:1205–1229PubMedCrossRef

22.

Zhang H, Mao Y, Chen X et al (2019) Magnetic resonance imaging radiomics in categorizing ovarian masses and predicting clinical outcome: A preliminary study. Eur Radiol 29:3358–3371PubMedCrossRef

23.

Lee EYP, An H, Perucho JAU et al (2020) Functional tumour burden of peritoneal carcinomatosis derived from DWI could predict incomplete tumour debulking in advanced ovarian carcinoma. Eur Radiol 30:5551–5559PubMedCrossRef

24.

Mutch DG, Prat J (2014) 2014 FIGO staging for ovarian, fallopian tube and peritoneal cancer. Gynecol Oncol 133:401–404PubMedCrossRef

25.

Gillies RJ, Kinahan PE, Hricak H (2016) Radiomics: Images are more than pictures, they are data. Radiology 278:563–577PubMedCrossRef

26.

Meng X, Xia W, Xie P et al (2019) Preoperative radiomic signature based on multiparametric magnetic resonance imaging for noninvasive evaluation of biological characteristics in rectal cancer. Eur Radiol 29:3200–3209PubMedCrossRef

27.

Huang YQ, Liang CH, He L et al (2016) Development and validation of a radiomics nomogram for preoperative prediction of lymph node metastasis in colorectal cancer. J Clin Oncol 34:2157–2164PubMedCrossRef

28.

Zheng J, Kong J, Wu S et al (2019) Development of a noninvasive tool to preoperatively evaluate the muscular invasiveness of bladder cancer using a radiomics approach. Cancer 125:4388–4398PubMedCrossRef

29.

Sun R, Limkin EJ, Vakalopoulou M et al (2018) A radiomics approach to assess tumour-infiltrating CD8 cells and response to anti-PD-1 or anti-PD-L1 immunotherapy: An imaging biomarker, retrospective multicohort study. Lancet Oncol 19:1180–1191PubMedCrossRef

30.

Messal HA, Alt S, Ferreira RMM et al (2019) Tissue curvature and apicobasal mechanical tension imbalance instruct cancer morphogenesis. Nature 566:126–130PubMedPubMedCentralCrossRef

31.

Bertucci F, Birnbaum D (2009) Distant metastasis: Not out of reach any more. J Biol 8:28PubMedPubMedCentralCrossRef

32.

Michielsen K, Dresen R, Vanslembrouck R et al (2017) Diagnostic value of whole body diffusion-weighted MRI compared to computed tomography for pre-operative assessment of patients suspected for ovarian cancer. Eur J Cancer 83:88–98PubMedCrossRef

33.

Roze JF, Hoogendam JP, van de Wetering FT et al (2018) Positron emission tomography (PET) and magnetic resonance imaging (MRI) for assessing tumour resectability in advanced epithelial ovarian/fallopian tube/primary peritoneal cancer. Cochrane Database Syst Rev 10:CD012567PubMed

34.

Wright AA, Bohlke K, Armstrong DK et al (2016) Neoadjuvant chemotherapy for newly diagnosed, advanced ovarian cancer: Society of Gynecologic Oncology and American Society of Clinical Oncology Clinical practice guideline. J Clin Oncol 34:3460–3473PubMedCrossRef

35.

Chang SJ, Hodeib M, Chang J, Bristow RE (2013) Survival impact of complete cytoreduction to no gross residual disease for advanced-stage ovarian cancer: A meta-analysis. Gynecol Oncol 130:493–498PubMedCrossRef

36.

Varghese BA, Cen SY, Hwang DH, Duddalwar VA (2019) Texture analysis of imaging: What radiologists need to know. AJR Am J Roentgenol 212:520–528PubMedCrossRef

37.

Rizzo S, Botta F, Raimondi S et al (2018) Radiomics of high-grade serous ovarian cancer: Association between quantitative CT features, residual tumour and disease progression within 12 months. Eur Radiol 28:4849–4859PubMedCrossRef

38.

Lu H, Arshad M, Thornton A et al (2019) A mathematical-descriptor of tumor-mesoscopic-structure from computed-tomography images annotates prognostic- and molecular-phenotypes of epithelial ovarian cancer. Nat Commun 10:764PubMedPubMedCentralCrossRef

39.

Kim BR, Kim JH, Ahn SJ et al (2019) CT prediction of resectability and prognosis in patients with pancreatic ductal adenocarcinoma after neoadjuvant treatment using image findings and texture analysis. Eur Radiol 29:362–372PubMedCrossRef

40.

Vargas HA, Veeraraghavan H, Micco M et al (2017) A novel representation of inter-site tumour heterogeneity from pre-treatment computed tomography textures classifies ovarian cancers by clinical outcome. Eur Radiol 27:3991–4001PubMedPubMedCentralCrossRef

41.

Pinto MP, Balmaceda C, Bravo ML et al (2018) Patients inflammatory status and CD4+/CD8+ intraepithelial tumor lymphocyte infiltration are predictors of outcomes in high-grade serous ovarian cancer. Gynecol Oncol 151:10–17PubMedCrossRef

42.

Li Y, Jian J, Pickhardt PJ et al (2020) MRI-based machine learning for differentiating borderline from malignant epithelial ovarian tumors: A multicenter study. J Magn Reson Imaging 52:897–904PubMedCrossRef

43.

Nougaret S, Lakhman Y, Gönen M et al (2019) High-grade serous ovarian cancer: Associations between BRCA mutation status, CT imaging phenotypes, and clinical outcomes. Radiology 285:472–481CrossRef

44.

Torres D, Wang C, Kumar A et al (2018) Factors that influence survival in high-grade serous ovarian cancer: A complex relationship between molecular subtype, disease dissemination, and operability. Gynecol Oncol 150:227–232PubMedPubMedCentralCrossRef

Title: Noninvasive prediction of residual disease for advanced high-grade serous ovarian carcinoma by MRI-based radiomic-clinical nomogram
Authors: Haiming Li
Rui Zhang
Ruimin Li
Wei Xia
Xiaojun Chen
Jiayi Zhang
Songqi Cai
Yong’ai Li
Shuhui Zhao
Jinwei Qiang
Weijun Peng
Yajia Gu
Xin Gao
Publication date: 01-10-2021
Publisher: Springer Berlin Heidelberg
Keywords: Magnetic Resonance Imaging
Magnetic Resonance Imaging
Ovarian Cancer
Ovarian Cancer
Published in: European Radiology / Issue 10/2021
Print ISSN: 0938-7994
Electronic ISSN: 1432-1084
DOI: https://doi.org/10.1007/s00330-021-07902-0

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Noninvasive prediction of residual disease for advanced high-grade serous ovarian carcinoma by MRI-based radiomic-clinical nomogram

Abstract

Objectives

Methods

Results

Conclusions

Key Points

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Objectives

Methods

Results

Conclusions

Key Points

Please log in to get access to this content

Other articles of this Issue 10/2021

Macrotrabecular-massive hepatocellular carcinoma: imaging identification and prediction based on gadoxetic acid–enhanced magnetic resonance imaging

Radiomics approach for survival prediction in chronic obstructive pulmonary disease

Expanding diagnostic tools for dysthyroid optic neuropathy: how quantitative MRI can be used to visualize and measure orbital inflammation

The presence of contrast agent increases organ radiation dose in contrast-enhanced CT

Clinical T1aN0M0 lung cancer: differences in clinicopathological patterns and oncological outcomes based on the findings on high-resolution computed tomography

Early prediction of 1-year tumor response of hepatocellular carcinoma with lipiodol deposition pattern through post-embolization cone-beam computed tomography during conventional transarterial chemoembolization